Skip to main content
SpringerLink
Log in

Lungenkrebsscreening bei Frauen braucht hormonelle Alternative

Lung cancer screening in women requires hormone-based alternatives

  • Leserbriefe
  • Published:
Die Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abdel-Rahman O et al (2020) Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis. Int J Clin Oncol 25(5):885–891

    Article  CAS  PubMed  Google Scholar 

  2. Clague J, Reynolds P et al (2011) Menopausal hormone therapy does not influence lung cancer risk: results from the California Teachers Study. Cancer Epidemiol Biomarkers Prev 20(3):560–564

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Elliott AM, Hannaford PC (2006) Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners’ Oral Contraception Study. Contraception 73(4):331–335

    Article  CAS  PubMed  Google Scholar 

  4. Kreuzer M, Gerken M et al (2003) Hormonal factors and risk of lung cancer among women? Int J Epidemiol 2(2):263–271

    Article  Google Scholar 

  5. Mikkola TS et al (2016) Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. Menopause 23(11):1199–1203

    Article  PubMed  Google Scholar 

  6. Musial C, Zaucha R et al (2021) Plausible role of estrogens in pathogenesis, progression and therapy of lung cancer. Int J Environ Res Public Health 18:648. https://doi.org/10.3390/ijerph18020648

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Pesatori AC, Carugno M et al (2013) Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO). Br J Cancer 109(7):1954–1964

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Titan AL, He H et al (2020) The influence of hormone replacement therapy on lung cancer incidence and mortality. J Thorac Cardiovasc Surg 159(4):1546–1556.e4

    Article  PubMed  Google Scholar 

  9. Triebner K et al (2017) Menopause is associated with accelerated lung function decline. Am J Respir Crit Gare Med 195:1058–1065

    Article  Google Scholar 

  10. Vachani A et al (2021) The probability of lung cancer in patients with incidentally detected pulmonary nodules: clinical characteristics and accuracy of prediction models. Chest. https://doi.org/10.1016/j.chest.2021.07.2168

    Article  PubMed  Google Scholar 

  11. Whitcomb BW et al (2018) Cigarette smoking and risk of earlynatural menopause. Am J Epidemiol 187:696–704

    Article  PubMed  Google Scholar 

  12. Wu W, Yin Z‑H et al (2014) Association of oral contraceptives use and lung cancer risk among women: an updated meta-analysis based on cohort and case-control studies. Asian Pac J Cancer Prev 15(3):1205–1210

    Article  PubMed  Google Scholar 

  13. Yao Y, Gu X et al (2013) Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis. Plos One 8(8):e71236

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eytystr. 14, 89075, Ulm, Deutschland

    J. M. Wenderlein

Authors
  1. J. M. Wenderlein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. M. Wenderlein.

Ethics declarations

Interessenkonflikt

J.M. Wenderlein gibt an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wenderlein, J.M. Lungenkrebsscreening bei Frauen braucht hormonelle Alternative. Onkologie 29, 370–372 (2023). https://doi.org/10.1007/s00761-022-01202-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-022-01202-y

Search

Navigation